Ok, so it’s not the 15th century  but the notion of an instantaneous transfer of sovereignty resonates as I watch the flow of venture capital from Therapeutics to other technologies in healthcare.  At least there are those who still believe that investing in healthcare is good business (phew! It was scary for a few years).  Sure we’re also shifting to invest in those disruptive technologies that are emerging from the long-awaited collision of healthcare and IT – happy to be part of that ride – but I still believe that Therapeutics will remain an important part of managing our health (check out portfolio co. Angiochem and Alethia). The beauty of our $270 million fund is that we can, and will, invest across different sectors in healthcare.  In fact, we invest in innovative therapeutics and medical technology, diagnostics, health IT, mobile technologies and services, as well as robotics and automation.  By design, our fund is mixing it up on the “black box” component and look to all technologies that can positively impact global healthcare productivity, efficiency and patient outcomes.  But I don’t expect that Therapeutics will give up the throne and historical position of undisputed ruler easily – M&A activity in the industry was robust for Therapeutics in 2012 with transactions totaling $109.4 billion globally. Venture financing in the sector was also active, with $9.5 billion raised, up from $7.7 billion in in 2011.   While other exciting technologies continue their ascent, I’ll be there to support the climb.  In the meantime, all I can say is “ Long Live Therapeutics”.

Ela Borenstein

Ela Borenstein

read more